公开(公告)号：US10815240B2

公开(公告)日：2020-10-27

申请号：US16502703

申请日：2019-07-03

申请人： Pfizer Inc.

发明人： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC分类号： C07D487/04 ,  C07D249/08

摘要： The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20210009601A1

公开(公告)日：2021-01-14

申请号：US17036849

申请日：2020-09-29

申请人： Pfizer Inc.

发明人： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC分类号： C07D487/04 ,  C07D249/08

摘要： The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20200123159A1

公开(公告)日：2020-04-23

申请号：US16502703

申请日：2019-07-03

申请人： Pfizer Inc.

发明人： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC分类号： C07D487/04 ,  C07D249/08

摘要： The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20240076301A1

公开(公告)日：2024-03-07

申请号：US18268795

申请日：2021-12-22

申请人： Pfizer Inc. ,  EFFECTOR THERAPEUTICS, INC.

发明人： Kapildev Kashmirilal Arora ,  Wesley Dewitt Clark ,  David Malcolm Crowe ,  Jason Gray

IPC分类号： C07D519/00

CPC分类号： C07D519/00

摘要： The present invention relates to solid forms of 7-(5-chloro-2-(3-(5-cyano-6-(1-(3,3-difluorocyclobutyl)piperidin-4-yl)(methyl)amino)-2-methyl-4-oxopyrido[3,4-d]pyrimidin-3(4H)-yl)prop-1-yn-1-yl)phenyl)-N-(methylsulfonyl)thieno[3,2-b]pyridine-3-carboxamide, to pharmaceutical compositions comprising such solid forms, and to methods of using such solid forms and pharmaceutical compositions for the treatment of cancer.

公开(公告)号：US11254684B2

公开(公告)日：2022-02-22

申请号：US17036849

申请日：2020-09-29

申请人： Pfizer Inc.

发明人： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC分类号： C07D487/04 ,  C07D249/08

摘要： The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20180148432A1

公开(公告)日：2018-05-31

申请号：US15820679

申请日：2017-11-22

申请人： Pfizer Inc.

发明人： Natasha Mariam Kablaoui ,  Michael Eric Green ,  Justin Ian Montgomery ,  Michael Aaron Brodney ,  Patrick Robert Verhoest ,  Gregory Wayne Kauffman ,  Danica Antonia Rankic ,  Scot Richard Mente ,  Bruce Nelsen Rogers ,  Kapildev Kashmirilal Arora ,  Matthew Francis Dunn

IPC分类号： C07D403/04 ,  C07D417/04 ,  A61P25/00 ,  C07D231/20 ,  C07D413/04

CPC分类号： C07D403/04 ,  A61P25/00 ,  C07B2200/13 ,  C07D231/20 ,  C07D413/04 ,  C07D417/04

摘要： The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.

公开(公告)号：US12018031B2

公开(公告)日：2024-06-25

申请号：US17572089

申请日：2022-01-10

申请人： Pfizer Inc.

发明人： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC分类号： C07D487/04 ,  C07D249/08

CPC分类号： C07D487/04 ,  C07D249/08 ,  C07B2200/13

摘要： The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US20220127274A1

公开(公告)日：2022-04-28

申请号：US17572089

申请日：2022-01-10

申请人： Pfizer Inc.

发明人： Kapildev Kashmirilal Arora ,  Jacob Cole DeForest ,  Andrew Kevern Hills ,  Brian Patrick Jones ,  Kris Nicole Jones ,  Chad Arthur Lewis ,  Anil Mahadeo Rane

IPC分类号： C07D487/04 ,  C07D249/08

摘要： The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.

公开(公告)号：US10316021B2

公开(公告)日：2019-06-11

申请号：US15820679

申请日：2017-11-22

申请人： Pfizer Inc.

发明人： Natasha Mariam Kablaoui ,  Michael Eric Green ,  Justin Ian Montgomery ,  Michael Aaron Brodney ,  Patrick Robert Verhoest ,  Gregory Wayne Kauffman ,  Danica Antonia Rankic ,  Scot Richard Mente ,  Bruce Nelsen Rogers ,  Kapildev Kashmirilal Arora ,  Matthew Francis Dunn

IPC分类号： C07D403/04 ,  C07D231/20 ,  C07D413/04 ,  C07D417/04 ,  A61P25/00

摘要： The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.